BioPharmSignal logoBioPharmSignal

Biotech News

Veradigm Provides Business and Strategy Update

Veradigm (MDRX)VeradigmCompany update

CHICAGO --(BUSINESS WIRE)--Feb. 17, 2026-- Veradigm ® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026.

Related news

MDRXVeradigm2026-05-26 20:10 EST

Veradigm Files 2023 and 2024 Form 10-K

MDRXVeradigm2026-05-26 12:01 EST

Veradigm to Release Business Update May 26th and Host Investor Call May 27th

View all latest news

Veradigm

Veradigm is a healthcare information and analytics company focused on software, data, and workflow tools for providers and life-sciences customers. Its business is more about information infrastructure than therapeutic innovation.

Recent company news

MDRXVeradigm2026-05-26 20:10 EST

Veradigm Files 2023 and 2024 Form 10-K

MDRXVeradigm2026-05-26 12:01 EST

Veradigm to Release Business Update May 26th and Host Investor Call May 27th

MDRXVeradigm2026-05-06 20:01 EST

Veradigm Launches Health Network Architecture to Level the Playing Field for Independent Practices

MDRXVeradigm2026-05-06 12:01 EST

Veradigm Survey: Independent Practices Rely on Technology to Stay Independent

MDRXVeradigm2026-04-28 20:01 EST

Veradigm Receives KLAS 2026 Points of Light Award for Embedding SDOH Data in Provider EHR Workflows

Stock data

Close
4.80 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States